

Monoclonal Anti-Chikungunya Virus E2 Envelope Glycoprotein, Clone CHK-48 (produced *in vitro*)

Catalog No. NR-44002

For research use only. Not for human use.

Contributor:

Michael S. Diamond, M.D., Ph.D., Departments of Medicine, Molecular Microbiology, Pathology and Immunology, Washington University School of Medicine, Saint Louis, Missouri, USA

Manufacturer:

BEI Resources

Product Description:

Antibody Class: IgG2c λ

Mouse monoclonal antibody prepared against the E2 envelope glycoprotein of chikungunya virus (CHIKV) was purified from clone CHK-48 hybridoma supernatant by protein G affinity chromatography. The B cell hybridoma was generated by the fusion of P3X63Ag8.653 mouse myeloma cells with immunized mouse splenocytes. The clone CHK-48 antibody is reported to neutralize a variety of CHIKV strains *in vitro*, and to cross-react with o'nyong-nyong virus as well as Getah, Mayaro, and Una viruses.^{1,2}

Material Provided:

Each vial of NR-44002 contains approximately 100 μ L of purified monoclonal antibody in PBS. The concentration, expressed as mg per mL, is shown on the Certificate of Analysis.

Packaging/Storage:

NR-44002 was packaged aseptically in screw-capped plastic cryovials and is provided frozen on dry ice. The item should be stored at -20°C or colder immediately upon arrival. Freeze-thaw cycles should be avoided.

Functional Activity:

NR-44002 is reactive on CHIKV-infected Vero cells in indirect immunofluorescence assays. See Certificate of Analysis for details. The antibody is also reported to function in ELISA as well as flow cytometry and western blot assays.¹

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Monoclonal Anti-Chikungunya Virus E2 Envelope Glycoprotein, Clone CHK-48 (produced *in vitro*), NR-44002."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services,

Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmb15/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Diamond, M. S., Personal Communication.
2. Pal, P., et al. "Development of a Highly Protective Combination Monoclonal Antibody Therapy against Chikungunya Virus." PLoS Pathog. 9 (2013): e1003312. PubMed: 23637602.

ATCC® is a trademark of the American Type Culture Collection.

